MYCN amplification
MYCN amplification
|
Neuroblastoma
Neuroblastoma
|
DHODH inhibitor
Sensitive: D – Preclinical
Cell Death Dis - 2 weeks
|
No biomarker
No biomarker
|
Neuroblastoma
Neuroblastoma
|
dinutuximab beta
BeiGene Press Release - 4 weeks
|
No biomarker
No biomarker
|
Neuroblastoma
Neuroblastoma
|
doxorubicin hydrochloride
|
No biomarker
No biomarker
|
Neuroblastoma
Neuroblastoma
|
|
No biomarker
No biomarker
|
Neuroblastoma
Neuroblastoma
|
|
No biomarker
No biomarker
|
Neuroblastoma
Neuroblastoma
|
|
No biomarker
No biomarker
|
Neuroblastoma
Neuroblastoma
|
|
ALK positive
ALK positive
|
Neuroblastoma
Neuroblastoma
|
crizotinib
Sensitive: C3 – Early Trials
|
|
Neuroblastoma
Neuroblastoma
|
crizotinib
Sensitive: C3 – Early Trials
|
ATRX mutation
ATRX mutation
|
Neuroblastoma
Neuroblastoma
|
AZD1775
Sensitive: C3 – Early Trials
|
ALK rearrangement + ALK R1275Q + TP53 mutation
ALK rearrangement + ALK R1275Q + TP53 mutation
|
Neuroblastoma
Neuroblastoma
|
crizotinib
Resistant: C4 – Case Studies
|
PGBD5 overexpression
PGBD5 overexpression
|
Neuroblastoma
Neuroblastoma
|
cisplatin
Sensitive: D – Preclinical
|
PGBD5 overexpression
PGBD5 overexpression
|
Neuroblastoma
Neuroblastoma
|
AZD6738
Sensitive: D – Preclinical
|
PGBD5 underexpression
PGBD5 underexpression
|
Neuroblastoma
Neuroblastoma
|
AZD6738
Sensitive: D – Preclinical
|
|
Neuroblastoma
Neuroblastoma
|
TAE-684
Resistant: D – Preclinical
|
MYCN amplification
MYCN amplification
|
Neuroblastoma
Neuroblastoma
|
GSK2816126 + MTX110
Sensitive: D – Preclinical
|
MYCN amplification
MYCN amplification
|
Neuroblastoma
Neuroblastoma
|
OTX015
Sensitive: D – Preclinical
|
MYCN amplification
MYCN amplification
|
Neuroblastoma
Neuroblastoma
|
JQ-1 + MTX110
Sensitive: D – Preclinical
|
MYCN amplification
MYCN amplification
|
Neuroblastoma
Neuroblastoma
|
brigatinib
Resistant: D – Preclinical
|
MYCN amplification
MYCN amplification
|
Neuroblastoma
Neuroblastoma
|
crizotinib
Resistant: D – Preclinical
|
|
Neuroblastoma
Neuroblastoma
|
crizotinib
Resistant: D – Preclinical
|
|
Neuroblastoma
Neuroblastoma
|
AZD3463
Sensitive: D – Preclinical
|
|
Neuroblastoma
Neuroblastoma
|
alectinib
Sensitive: D – Preclinical
|
ALK amplification
ALK amplification
|
Neuroblastoma
Neuroblastoma
|
alectinib
Sensitive: D – Preclinical
|
|
Neuroblastoma
Neuroblastoma
|
lorlatinib
Sensitive: D – Preclinical
|
|
Neuroblastoma
Neuroblastoma
|
lorlatinib
Sensitive: D – Preclinical
|
|
Neuroblastoma
Neuroblastoma
|
TAE-684
Sensitive: D – Preclinical
|
MYCN amplification + ALK rearrangement
MYCN amplification + ALK rearrangement
|
Neuroblastoma
Neuroblastoma
|
brigatinib
Sensitive: D – Preclinical
|
MYCN amplification + ALK F1174V
MYCN amplification + ALK F1174V
|
Neuroblastoma
Neuroblastoma
|
brigatinib
Sensitive: D – Preclinical
|
MYCN amplification + ALK F1174V
MYCN amplification + ALK F1174V
|
Neuroblastoma
Neuroblastoma
|
crizotinib
Sensitive: D – Preclinical
|
NF1 underexpression
NF1 underexpression
|
Neuroblastoma
Neuroblastoma
|
binimetinib
Sensitive: D – Preclinical
|
MYCN amplification + ALK F1174L
MYCN amplification + ALK F1174L
|
Neuroblastoma
Neuroblastoma
|
lorlatinib
Sensitive: D – Preclinical
|
|
Neuroblastoma
Neuroblastoma
|
AZD3463
Sensitive: D – Preclinical
|
MYCN amplification + ALK rearrangement
MYCN amplification + ALK rearrangement
|
Neuroblastoma
Neuroblastoma
|
crizotinib
Sensitive: D – Preclinical
|
MYCN amplification + ALK R1275Q
MYCN amplification + ALK R1275Q
|
Neuroblastoma
Neuroblastoma
|
lorlatinib
Sensitive: D – Preclinical
|
ETV6-NTRK3 fusion
ETV6-NTRK3 fusion
|
Neuroblastoma
Neuroblastoma
|
TPX-0005
Sensitive: D – Preclinical
|
CD276 expression
CD276 expression
|
Neuroblastoma
Neuroblastoma
|
B7H3-targeted CAR-T immunotherapy
Sensitive: D – Preclinical
|
TERT rearrangement
TERT rearrangement
|
Neuroblastoma
Neuroblastoma
|
OTX015
Sensitive: D – Preclinical
|
ALK positive
ALK positive
|
Neuroblastoma
Neuroblastoma
|
CAR-T immunotherapy
Sensitive: D – Preclinical
|
|
Neuroblastoma
Neuroblastoma
|
ASN007
Sensitive: D – Preclinical
|
